PSMA PET In Prostate Cancer: Opportunities And Nuances

Key Takeaways:

• PSMA PET was described as changing staging and management in initial and recurrent prostate cancer settings.
• Interpretation differences and implementation barriers were presented as limits on consistent use across sites.
• PSMA PET was framed as relevant to radioligand-therapy selection while related metrics and response frameworks remain under development.

The review notes that the modality can identify disease sites that conventional imaging may miss, which can affect staging or restaging in some clinical settings. Investigators connect these findings to how tumor extent is categorized and how subsequent care pathways are considered. Overall, the authors portray the scan as influential because imaging results can redefine disease location and reshape the framework used for later planning.

Across unfavorable intermediate-risk disease, high-risk disease, and biochemical recurrence, the authors report management changes spanning radiation planning, systemic therapy use, and salvage selection. PSMA PET is described as supporting more accurate staging, restaging, and treatment planning in these scenarios. On the radiation side, findings informed target delineation, dose escalation, elective nodal coverage, and decisions about salvage radiotherapy after prior treatment. The review also describes instances in which imaging findings supported therapy initiation, escalation, or a different salvage approach based on recurrence pattern. Together, these examples present PSMA PET as a planning tool whose impact depends on the treatment context.

The authors caution that interpretation can vary because tracers differ in biodistribution, and scanners and acquisition protocols also differ across sites. Reader experience adds another source of variation, particularly when clinical scenarios and lesion patterns require nuanced classification. The review describes urinary activity as a technical obstacle in the pelvis and notes that benign or non-prostate findings can mimic malignancy. These factors position interpretation as a key determinant of how confidently PSMA PET findings are applied.

Broader uptake also appears shaped by infrastructure limits, reimbursement variability, reporting detail, and shortages in the nuclear medicine workforce. The review notes that access can differ across practice settings, while incomplete reports may leave referring teams without the detail needed for treatment planning. In response, the authors discuss standardized reporting, accreditation, education, and AI-supported reporting or quantification, including use before PSMA-targeted radioligand therapy. Overall, the review portrays adoption as dependent on systems and workflow as much as on scan capability.

The authors also frame PSMA PET as part of eligibility assessment before PSMA-targeted radioligand therapy and note FDA-approved imaging agents in that setting. Alongside that theranostic role, the review describes PSMA PET-derived metrics, standardized response criteria, and AI-assisted quantification as evolving components of assessment. Researchers add that clinical benefit will require future prospective, outcome-driven validation. In sum, the review presents PSMA PET as an established influence on clinical imaging while remaining an evolving platform for treatment selection and response assessment.